Autoimmunity in Alzheimer's disease as evidenced by plasma immunoreactivity against RAGE and Aβ42: Complication of diabetes

Shyamala Mruthinti, Rosann F. Schade, Dean U Harrell, Nidhi K Gulati, S. Swamy-Mruthinti, Gregory P Lee, Jerry J. Buccafusco

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Features of autoimmunity have been associated with both Alzheimer's disease (AD) and with diabetes. In both diseases high levels of advanced glycation end products (AGEs) and their receptor (RAGE) have been detected in tissues and in the circulation. In addition high titers of antibodies directed against a RAGE-like peptide occur in the circulation. In this study we report the presence of auto-antibodies directed against RAGE and the cytotoxic amyloid peptide Aβ42 in plasma samples derived from four study groups. Anti-RAGE IgG titers were greatest in the AD-diabetic cohort. They were followed in decreasing order by the AD-non-diabetic cohort, the elderly diabetic cohort, and lastly by the control non-diabetic elderly cohort. The same profile of IgG differences was evident for the anti-Aβ42 titers. When all of the data were combined, there was a strong linear correlation between the RAGE and Aβ42 titers suggesting that the two peptides exist as a tight complex in plasma. Plasma IgG titers were not correlated with cognitive status except that AD and AD-diabetic participants were significantly cognitively impaired relative to the two non-AD groups. There also was no significant correlation between IgG titers and subject age, except that there was a trend for a negative slope for the AD participants and a positive slope for the control participants. In keeping with the human data, we also report that chemically-induced diabetes in rats was associated with high levels of AGEs, anti-RAGE-like IgGs, and anti-Aβ42-like IgGs. For non-diabetic rats, there was a clear age-dependency regarding the magnitude of the IgG levels. These data support the concept of an interrelationship between diabetes and AD. For both diseases one underlying contributing factor to cytotoxicity could be the development of an autoimmune response triggered by the presence of AGEs and amyloid peptides.

Original languageEnglish (US)
Pages (from-to)229-235
Number of pages7
JournalCurrent Alzheimer Research
Volume3
Issue number3
DOIs
StatePublished - Jul 10 2006

Fingerprint

Diabetes Complications
Autoimmunity
Alzheimer Disease
Immunoglobulin G
Amyloid
Peptides
Advanced Glycosylation End Products
Antibodies

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Autoimmunity in Alzheimer's disease as evidenced by plasma immunoreactivity against RAGE and Aβ42 : Complication of diabetes. / Mruthinti, Shyamala; Schade, Rosann F.; Harrell, Dean U; Gulati, Nidhi K; Swamy-Mruthinti, S.; Lee, Gregory P; Buccafusco, Jerry J.

In: Current Alzheimer Research, Vol. 3, No. 3, 10.07.2006, p. 229-235.

Research output: Contribution to journalArticle

Mruthinti, Shyamala ; Schade, Rosann F. ; Harrell, Dean U ; Gulati, Nidhi K ; Swamy-Mruthinti, S. ; Lee, Gregory P ; Buccafusco, Jerry J. / Autoimmunity in Alzheimer's disease as evidenced by plasma immunoreactivity against RAGE and Aβ42 : Complication of diabetes. In: Current Alzheimer Research. 2006 ; Vol. 3, No. 3. pp. 229-235.
@article{02d3283dd8bb489ba4a6e07ed7530024,
title = "Autoimmunity in Alzheimer's disease as evidenced by plasma immunoreactivity against RAGE and Aβ42: Complication of diabetes",
abstract = "Features of autoimmunity have been associated with both Alzheimer's disease (AD) and with diabetes. In both diseases high levels of advanced glycation end products (AGEs) and their receptor (RAGE) have been detected in tissues and in the circulation. In addition high titers of antibodies directed against a RAGE-like peptide occur in the circulation. In this study we report the presence of auto-antibodies directed against RAGE and the cytotoxic amyloid peptide Aβ42 in plasma samples derived from four study groups. Anti-RAGE IgG titers were greatest in the AD-diabetic cohort. They were followed in decreasing order by the AD-non-diabetic cohort, the elderly diabetic cohort, and lastly by the control non-diabetic elderly cohort. The same profile of IgG differences was evident for the anti-Aβ42 titers. When all of the data were combined, there was a strong linear correlation between the RAGE and Aβ42 titers suggesting that the two peptides exist as a tight complex in plasma. Plasma IgG titers were not correlated with cognitive status except that AD and AD-diabetic participants were significantly cognitively impaired relative to the two non-AD groups. There also was no significant correlation between IgG titers and subject age, except that there was a trend for a negative slope for the AD participants and a positive slope for the control participants. In keeping with the human data, we also report that chemically-induced diabetes in rats was associated with high levels of AGEs, anti-RAGE-like IgGs, and anti-Aβ42-like IgGs. For non-diabetic rats, there was a clear age-dependency regarding the magnitude of the IgG levels. These data support the concept of an interrelationship between diabetes and AD. For both diseases one underlying contributing factor to cytotoxicity could be the development of an autoimmune response triggered by the presence of AGEs and amyloid peptides.",
author = "Shyamala Mruthinti and Schade, {Rosann F.} and Harrell, {Dean U} and Gulati, {Nidhi K} and S. Swamy-Mruthinti and Lee, {Gregory P} and Buccafusco, {Jerry J.}",
year = "2006",
month = "7",
day = "10",
doi = "10.2174/156720506777632899",
language = "English (US)",
volume = "3",
pages = "229--235",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Autoimmunity in Alzheimer's disease as evidenced by plasma immunoreactivity against RAGE and Aβ42

T2 - Complication of diabetes

AU - Mruthinti, Shyamala

AU - Schade, Rosann F.

AU - Harrell, Dean U

AU - Gulati, Nidhi K

AU - Swamy-Mruthinti, S.

AU - Lee, Gregory P

AU - Buccafusco, Jerry J.

PY - 2006/7/10

Y1 - 2006/7/10

N2 - Features of autoimmunity have been associated with both Alzheimer's disease (AD) and with diabetes. In both diseases high levels of advanced glycation end products (AGEs) and their receptor (RAGE) have been detected in tissues and in the circulation. In addition high titers of antibodies directed against a RAGE-like peptide occur in the circulation. In this study we report the presence of auto-antibodies directed against RAGE and the cytotoxic amyloid peptide Aβ42 in plasma samples derived from four study groups. Anti-RAGE IgG titers were greatest in the AD-diabetic cohort. They were followed in decreasing order by the AD-non-diabetic cohort, the elderly diabetic cohort, and lastly by the control non-diabetic elderly cohort. The same profile of IgG differences was evident for the anti-Aβ42 titers. When all of the data were combined, there was a strong linear correlation between the RAGE and Aβ42 titers suggesting that the two peptides exist as a tight complex in plasma. Plasma IgG titers were not correlated with cognitive status except that AD and AD-diabetic participants were significantly cognitively impaired relative to the two non-AD groups. There also was no significant correlation between IgG titers and subject age, except that there was a trend for a negative slope for the AD participants and a positive slope for the control participants. In keeping with the human data, we also report that chemically-induced diabetes in rats was associated with high levels of AGEs, anti-RAGE-like IgGs, and anti-Aβ42-like IgGs. For non-diabetic rats, there was a clear age-dependency regarding the magnitude of the IgG levels. These data support the concept of an interrelationship between diabetes and AD. For both diseases one underlying contributing factor to cytotoxicity could be the development of an autoimmune response triggered by the presence of AGEs and amyloid peptides.

AB - Features of autoimmunity have been associated with both Alzheimer's disease (AD) and with diabetes. In both diseases high levels of advanced glycation end products (AGEs) and their receptor (RAGE) have been detected in tissues and in the circulation. In addition high titers of antibodies directed against a RAGE-like peptide occur in the circulation. In this study we report the presence of auto-antibodies directed against RAGE and the cytotoxic amyloid peptide Aβ42 in plasma samples derived from four study groups. Anti-RAGE IgG titers were greatest in the AD-diabetic cohort. They were followed in decreasing order by the AD-non-diabetic cohort, the elderly diabetic cohort, and lastly by the control non-diabetic elderly cohort. The same profile of IgG differences was evident for the anti-Aβ42 titers. When all of the data were combined, there was a strong linear correlation between the RAGE and Aβ42 titers suggesting that the two peptides exist as a tight complex in plasma. Plasma IgG titers were not correlated with cognitive status except that AD and AD-diabetic participants were significantly cognitively impaired relative to the two non-AD groups. There also was no significant correlation between IgG titers and subject age, except that there was a trend for a negative slope for the AD participants and a positive slope for the control participants. In keeping with the human data, we also report that chemically-induced diabetes in rats was associated with high levels of AGEs, anti-RAGE-like IgGs, and anti-Aβ42-like IgGs. For non-diabetic rats, there was a clear age-dependency regarding the magnitude of the IgG levels. These data support the concept of an interrelationship between diabetes and AD. For both diseases one underlying contributing factor to cytotoxicity could be the development of an autoimmune response triggered by the presence of AGEs and amyloid peptides.

UR - http://www.scopus.com/inward/record.url?scp=33745630923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745630923&partnerID=8YFLogxK

U2 - 10.2174/156720506777632899

DO - 10.2174/156720506777632899

M3 - Article

C2 - 16842100

AN - SCOPUS:33745630923

VL - 3

SP - 229

EP - 235

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

IS - 3

ER -